richardycc
Diamond Member
- Apr 29, 2001
- 5,719
- 1
- 81
Where did all the shorts and selling pressure go? GNVC is up >5% on almost no volume.
Edit: Spoke too soon, back down to 1.89-1.91 range.
coming back up..C'mon 2 bucks!
$2.02 Real Time
What's the cause for the jump today?
I am so kicking myself for waiting till noon to even consider doubling down
anybody know the symbol for 5hour energy\living essentials?
cant find em for shit.
A buyout offer for Gen Growth Properties, but for only ~9 bucks/share! (It actually says for more than 9 dollars per share, no exact value is given.)
Here are the details:
http://www.prnewswire.com/news-rele...quire-general-growth-properties-84461832.html
I like the GNVC and GGWPQ pops...
News from test trials expected today or "very soon". If tomorrow, expect to see 3.00+. Lets hope for better than anticipated news.
Now there are rumors of partnerships and buyouts. Seems like a lot of who rah rah rah at the moment. Nothing solid yet.
News from test trials expected today or "very soon". If tomorrow, expect to see 3.00+. Lets hope for better than anticipated news.
Now there are rumors of partnerships and buyouts. Seems like a lot of who rah rah rah at the moment. Nothing solid yet.
I like the GNVC and GGWPQ pops...
Would you dip in for more at this point? I was thinking of getting a couple of hundred more shares but I feel nervous about cost averaging up.
Anyone have a time machine I can borrow?
GenVec of Gaithersburg wants a partner to help market its lead gene-therapy product outside the United States, chief executive Paul Fischer said Monday.
GenVec's TNFerade delivers a gene with a cancer-fighting protein directly to solid tumors. The pancreatic cancer treatment is currently in the last of three phases of testing. It is also being evaluated for use in other cancers, including rectal and esophageal.
Data from an interim analysis of a 330-patient trial, which is evaluating TNFerade's treatment of pancreatic cancer, will be available in late March or early April, Fischer said. Positive data will encourage potential partners, he said in an interview at the Biotechnology Industry Organization's CEO and Investor Conference in New York.